

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/561,449	11/22/2006	Luc Bouwens	BOUW3001/JEK	8208
2334 THOMAS, PILC BACON & THOMAS, PILC 625 SIATERS LANE FOURTH FLOOR ALEXANDRIA, VA 22314			EXAMINER	
			GAMETT, DANIEL C	
			ART UNIT	PAPER NUMBER
	.,		1647	
			MAIL DATE	DELIVERY MODE
			05/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/561,449 BOUWENS ET AL. Office Action Summary Examiner Art Unit DANIEL C. GAMETT 1647 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 22 November 2006. 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 45-61 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 45-61 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.

Attachment(s)

11 Notice of References Cited (PTO-892)
22 Notice of Draftsperson's Patient Drawing Review (PTO-948)
23 Paper No(s)Mail Date.
24 Interview Summary (PTO-413)
25 Paper No(s)Mail Date.
26 Other:
27 On Other:
28 On Other:
29 Other:
29 Other:
20 Other:
29 Other:
20 Other:
21 Other:
22 Other:
23 Other:
24 Other:
25 Other:
26 Other:
26 Other:
26 Other:
27 Other:
28 Other:
28 Other:
29 Other:
20 Other:
20

application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Copies of the certified copies of the priority documents have been received in this National Stage

Application/Control Number: 10/561,449 Page 2

Art Unit: 1647

DETAILED ACTION

 The preliminary amendments of 12/20/2005 have been entered in full. Claims 1-44 are cancelled. Claims 45-61 are under examination.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claim(s) 45-56 and 61, drawn to an in vitro method of generating insulin producing beta cells.
- Group II, claim(s) 57-60, drawn to a method of prevention or treatment of diabetes type 1 or type 2 comprising administration of a therapeutically effective amount of a combination of a human or humanised ligand of a EGF receptor, and a human or humanised ligand of the gp130 receptor.
- 3. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- 4. Group I recites the special technical feature, an in vitro method of generating insulin producing beta cells, which is not required by the methods or the products of Group II. Group I comprises the first recited method and product (a cell population).

Application/Control Number: 10/561,449 Page 3

Art Unit: 1647

5. Group II recites the special technical feature, a method of prevention or treatment of diabetes type 1 or type 2 comprising administration of a therapeutically effective amount of a combination of a human or humanised ligand of a EGF receptor, and a human or humanised ligand of the gp130 receptor, which is not required by the methods or the products of Group

I.

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel C. Gamett, PhD., whose telephone number is (571)272-1853. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on 571 272 0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Daniel C Gamett/ Examiner, Art Unit 1647